Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction - Wikidata - wikimedia - TriplyDB

Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction

Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction

http://www.wikidata.org/entity/Q36203267

about

Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists Developing therapies for heart failure with preserved ejection fraction: current state and future directions Phenotypic spectrum of heart failure with preserved ejection fraction.Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons Metabolomic fingerprint of heart failure with preserved ejection fraction.Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.Addition of B-Type Natriuretic Peptide to Existing Clinical Risk Scores Enhances Identification of Patients at Risk for Atrial Fibrillation Recurrence After Pulmonary Vein Isolation.Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction.Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.Heart failure with preserved ejection fraction: a clinical dilemma.Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study.Heart failure with preserved ejection fraction: uncertainties and dilemmas.Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.Targets for Heart Failure With Preserved Ejection Fraction.How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.Invasive Hemodynamic Assessment of Patients with Heart Failure and Pulmonary Hypertension.Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.Cardiac structural remodeling in hypertensive cardiomyopathy.Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study.Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance.Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Einstein, the Blind Men, and the Elephant: Making Sense of Heart Failure With Preserved Ejection Fraction.Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus.Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction.Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.Heart Failure With Preserved Ejection Fraction: A Perioperative Review.From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress.

P2860

Q26749044-9C383A05-9C84-4EDA-80AA-9D545C585E07 Q33639223-DB110615-1308-42D5-B38A-5E81A4F90238 Q33827302-D85C2A6F-6DBC-403A-830F-F5D6DEECF97C Q33917736-7E01735B-C726-4EF8-8BFA-4661654BDB0E Q34354197-FDECB640-F317-462C-9E81-EAC4342E8E34 Q34803690-17020B05-FEDF-4D03-A05B-4300ECC4BB37 Q35139959-6C70C649-CF68-4320-8AAF-118C9AA15081 Q35641415-31FE4FD7-A921-4B30-B344-F5DBD03F63B7 Q36266675-628FB3F5-EAA7-48F2-A133-F252C1701E97 Q36289226-4B337F00-6DDD-400C-8906-C0FF91F31A80 Q36463883-EB80D54F-5448-430D-8250-7AB60878A037 Q36676033-40F3240A-F5C9-4E25-A003-952F8B3A325D Q36985609-36D10E3E-35F2-4B7F-8FC4-6C530CE54457 Q37413536-B1BA53C1-FF22-420E-9B64-49703598D4E6 Q38195149-B6337744-D441-4FE8-B0AE-CD9A57F76502 Q38382930-65187800-E651-4139-B97F-D33909ED3306 Q38529003-71CE8528-786A-4250-BA6B-C227522F0EE8 Q38667037-2C5F3CA6-A1A8-4B97-B504-751E588728BD Q38688194-97C7C294-879B-41A5-AA0F-04422E4E1036 Q38802217-8ED19B14-9FEA-4819-8CD1-58C9E4B03F93 Q38807757-6155D46E-4C65-4498-816D-A0EDC4C65530 Q38854043-B5C33946-5714-4234-A63D-19B6DB75F19B Q39011756-6E6B3B18-B2CC-46EC-842D-CE084020BFB9 Q39076612-8B00B825-AE75-495F-BE4D-56D348D08ACA Q40161365-9C37BAEA-9B6D-4ACD-8C8B-16E9853CF5E4 Q40256097-29228897-8A91-48A2-B66F-477DBD7795A9 Q42062803-41A915F2-412C-4F54-A9D7-CC12B2CAD667 Q45947184-78C820C5-F760-4352-8497-5CE591EAE8DD Q46630081-AAAFC65D-8D76-4D06-86BE-5A3DA71410C8 Q47098884-3AA08CE4-31ED-4686-B01E-A54ADF300570 Q47726582-00AC4042-1407-4F02-BB4D-990B53B0DC68 Q47753168-C4F118F7-14F4-451E-AFB5-7E2E55D816D9 Q47854367-1CE04054-7ECC-49D4-AC8D-BD77BAEC8A59 Q50226285-BE8519E4-D634-4EE1-85E0-53721BE425F8 Q53241855-85C10E51-75DC-4BCB-8C3B-98D0AD351E28

P2860

Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction

http://www.wikidata.org/entity/Q36203267

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prevalence, clinical phenotype ...... th preserved ejection fraction

@ast

Prevalence, clinical phenotype ...... th preserved ejection fraction

@en

type

label

Prevalence, clinical phenotype ...... th preserved ejection fraction

@ast

Prevalence, clinical phenotype ...... th preserved ejection fraction

@en

prefLabel

Prevalence, clinical phenotype ...... th preserved ejection fraction

@ast

Prevalence, clinical phenotype ...... th preserved ejection fraction

@en

P1433

Q36203267-58196D44-3F6C-4D77-9317-14AE33A0E889

P1476

Q36203267-F2B942E5-9AD7-4027-8FD1-6F1A258F6EC4

P2093

Q36203267-228E765A-E3C0-4C90-9EF0-8B773AE1E8FC

Q36203267-85A6D1BD-F79C-44CF-9B27-781FA7DBAF58

Q36203267-A03F98C5-5C80-4814-B88E-0A6A3F3622BB

Q36203267-AACF3675-1B14-45B4-B677-E3D67961428A

Q36203267-E1C1AAE6-87A0-4E19-9FE5-FCA32D8FB364

P2860

Q36203267-0867AF4B-B665-4AF5-A877-42B03B2CC2E9

Q36203267-0D2FD6B1-8DE5-438C-BE4A-981B9AED96FD

Q36203267-11F9A977-A597-4B51-AD28-283A6EDB97DF

Q36203267-1CA28EEC-93E2-43FD-BC78-BB3BCA270381

Q36203267-2408515C-4A71-49FF-B72F-1FA74FCEEAF1

Q36203267-2478F382-EE26-4B70-8BD1-58D310C96D42

Q36203267-25F171DB-6E3E-4098-A4FC-0B489829AF09

Q36203267-294B44AE-3C66-4E0A-970A-27640F2659B1

Q36203267-38B78CDA-B8D3-4968-BB2F-347FAABC16EC

Q36203267-3FD0AB5A-34E0-4B0E-A081-7C05F3C412BF

P304

Q36203267-5E28630E-B3E6-46FF-9397-F29DE2370A0A

P31

Q36203267-9EA34F3C-C20D-4405-AFBA-BF4F2C63B163

P356

Q36203267-7BB4E4FA-C7B9-4761-A6AB-AB71ECE64086

P407

Q36203267-8508C959-1C6E-4F25-A7DB-A1E9A793061F

P433

Q36203267-4F5381E3-16DE-41EC-B1CB-1D40EACB6EF4

P478

Q36203267-347ECC40-E7B1-42EE-B54F-1FDCB239D999

P50

Q36203267-ACDDBFD7-D345-4E6E-B30D-5CD2F80E2C1B

Q36203267-F3F6B2B9-A8B2-4D62-8ADC-543531F88962

P577

Q36203267-8B9F5EEA-5F76-4BD3-BA11-2E90E699475F

P5875

Q36203267-69EC06CC-86EB-48A5-B5D7-120FD29B0400

P698

Q36203267-2012455B-56AC-40B5-B357-03E03AD551B6

P921

Q36203267-6276B88A-A07E-4AFF-B566-D02EBEA7EDF0

P932

Q36203267-58D2598E-A2C1-4703-ADA1-46D63A232901

P356

J.AMJCARD.2012.05.014

P1433

American Journal of Cardiology

P1476

Prevalence, clinical phenotype ...... th preserved ejection fraction

@en

P2093

Michael A Burke

http://www.w3.org/2001/XMLSchema#string

Nausheen Akhter

http://www.w3.org/2001/XMLSchema#string

Sanjiv J Shah

http://www.w3.org/2001/XMLSchema#string

Timothy M Loftus

http://www.w3.org/2001/XMLSchema#string

Venkatesh Y Anjan

http://www.w3.org/2001/XMLSchema#string

P2860

Heart failure with normal left ventricular ejection fraction

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Outcome of heart failure with preserved ejection fraction in a population-based study

Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Impact of obesity on plasma natriuretic peptide levels.

Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.

P304

870-876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJCARD.2012.05.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Gregg C. Fonarow

Mihai Gheorghiade

P577

2012-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225289324

http://www.w3.org/2001/XMLSchema#string

P698

22681864

http://www.w3.org/2001/XMLSchema#string

P921

P932

3432159

http://www.w3.org/2001/XMLSchema#string